Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

Merck reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products.

The company expects full-year adjusted earnings of $8.53 to $8.65 per share, up from its prior forecast of $8.44 to $8.59 per share.of Harpoon Therapeutics in January. The company develops immune-based cancer drugs. The guidance also includes a negative impact of 30 cents per share from foreign exchange changes.

Excluding acquisition and restructuring costs, Merck earned $2.07 per share for the first quarter. Both adjusted and non-adjusted profit for the period include the charge related to the Harpoon deal.patent expiration Merck is also cutting costs under a new restructuring program it announced in February. Those efforts aim to improve the manufacturing network of both its pharmaceutical division and animal health business.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Stocks making the biggest moves premarket: Robinhood, GameStop, Merck and moreThese are the stocks posting the largest moves in premarket trading.
Source: CNBC - 🏆 12. / 72 Read more »

Stocks making the biggest moves midday: GameStop, Merck, Carnival, Cintas and moreThese are the stocks posting the largest moves in midday trading.
Source: CNBC - 🏆 12. / 72 Read more »

Cramer's week ahead: Earnings from Tesla, Merck and Big TechCNBC’s Jim Cramer said next week’s PCE index report will be the real gauge of inflation.
Source: NBCLA - 🏆 319. / 59 Read more »

Cramer’s week ahead: Earnings from Tesla, Merck and Big TechCNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.
Source: CNBC - 🏆 12. / 72 Read more »